Core Viewpoint - Appili Therapeutics Inc. has entered into a second amending agreement with Aditxt, Inc. and Adivir, Inc. to modify the previously announced arrangement agreement for Aditxt to acquire all issued and outstanding Class A common shares of Appili through a court-approved plan of arrangement [1] Group 1: Transaction Details - The Outside Date for the transaction has been extended from August 30, 2024, to September 30, 2024 [2] - The deadline to convene the Company's special shareholders' meeting has also been changed to September 30, 2024 [2] - The deadline for Aditxt to complete the Financing has been modified from August 30, 2024, to September 15, 2024, or a later date as agreed by the Parties [2] Group 2: Company Overview - Appili Therapeutics is focused on drug development for infectious diseases and medical countermeasures, aiming to address urgent infections with unmet needs [4] - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate against biological weapon threats, and a topical antiparasitic treatment [4] - Appili is led by a proven management team and is positioned at the forefront of the global fight against infections [4]

Aditxt (NASDAQ:ADTX) stock is up on Wednesday after the biotech company announced an amended and restated merger agreement with Evofem Biosciences (OTCMKTS:EVFM).Aditxt notes that the merger agreement was amended and restated as Evofem Biosciences has some critical needs ahead of it. That includes interim financing and substituting cash for shares of ADTX stock in the merger.Aditxt also notes that it has acquired SOLOSEC from Lupin Limited. This grants Lupin Limited a potential of $84 million based on futur ...

MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secni ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into an amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and together ...

— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases —— Hello Alpha partnership boosts awareness of and access to Phexxi for millions of women —SAN DIEGO, June 27, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman's unique needs, to offer Phexxi® (lactic acid, citric acid and po ...

-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States -- SAN DIEGO, June 11, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses ...

As filed with the Securities and Exchange Commission June 5, 2024 Registration Statement No. 333-276588 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADITXT, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Delaware 23219 82-3204328 (I.R.S. Employer Identification Number) Classification Code Number) 2569 Wyandotte St., Suite 101 Mountainview, CA 94043 (650) 87 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39336 Aditxt, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3204328 ...

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: Received $1 million from Aditxt, Inc. (Nasdaq: ADTX) in May 2024 in consideration for reinstating and amending the Merger Agreement, as amended, between the companies. Aditxt agreed t ...

As filed with the Securities and Exchange Commission May 13, 2024 Registration Statement No. 333-276588 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADITXT, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 23219 82-3204328 (Address and telephone number of regis ...